FLT3 and acute myeloid leukemia: Mutated NPM1 and FLT3-ITD are now well-validated AML MRD targets [17, 27–31], and this IDH2-mutated cohort was further studied by dividing into two subgroups based on whether they also had either of these two mutations reported at initial diagnosis.